Thermo Fisher Scientific (TMO) reported solid top-line growth for the nine months ended September 27, 2025 (Q3 FY2025). Total Revenues increased to \(32.341B (2% organic growth), driving Diluted EPS to \)12.53 (up from \(11.75) and Net Income to \)4.740B. Q3 Adjusted Operating Margin improved 1.0 point to 23.3%, fueled by productivity gains, although Q3 Net Income was flat year-over-year due to higher restructuring costs ($135M recorded in the quarter).
Strategy and M&A Activity: The company remains focused on Life Sciences Solutions, which saw 8% organic revenue growth in Q3. TMO completed t
...